Syneos pharmaceutical sales representative salary
Evolus | Investor Relations
As a result, we paid Mr. Moatazedi a base salary of $361,731 for the fiscal year ended December 31, 2018, which represents his prorated base salary from May 2018 to December 2018. (4)As consideration for entering into the Moatazedi employment agreement, Mr. Moatazedi received a …
Investor Overview | Charles River Laboratories ...
leading its global pharmaceutical industry practice. Mr. Bertolini also serves as a director of. Bristol-Meyers Squibb Company and Idorsia, Ltd., a Swiss public company. He served as a director. of Genzyme Corporation until its merger with Sanofi-Aventis in 2011 and of Actelion until it was. acquired by Johnson & Johnson in June 2017. Mr.
Investors | Syneos Health
Each participant is eligible to vest in and receive a number of shares of the Company’s common stock ranging from 0% - 150% of the target number of PRSUs granted and set forth in the table above (for each executive, such target number, the “Target PRSUs”), based on the achievement of a return on invested capital goal over a three-year performance period (2021 – 2023) and adjusted ...
Investors | Syneos Health
Our CEO took a reduction of 30% in base salary, and other NEOs took reductions ranging. from 14% to 20% of salary from May 1, 2020 through September 30, 2020. In addition, all non-employee members of our Board voluntarily agreed to a 30% reduction in their cash retainers, exclusive of committee stipends, for the same period.
Overview | Laboratory Corporation of America Holdings
pharmaceutical and vaccine businesses from 2010 to 2018. Prior to becoming President, Global Human Health, 55. Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter’s extensive. President and. experience at Merck included global and U.S.-focused leadership roles spanning sales, marketing, and managed
Investors | Strongbridge Biopharma plc
Mar 03, 2021 · Product Sales. Our product sales in 2020 resulted from sales of Keveyis. We operate in one operating reporting segment. We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. We recognize net product sales at the time our product is received by the Customer.
Investor Relations | PPD
Mr. Scully commenced employment with the Company in May 2018. Amount reported in 2018 represents the portion of Mr. Scully’s annual base salary paid to him in 2018. Mr. Thakral’s annual base salary was increased from $400,000 to $450,000, effective November 1, 2019.
Evolus | Investor Relations
The Avelar employment agreement provides that Mr. Avelar is an at-will employee, sets forth his initial annual base salary of $400,000 (his current annual base salary is $424,000), and his eligibility to participate in employee benefit plans and programs generally available to other senior executives, as in effect from time to time.
Investor Relations :: Immunocore PLC
If Syneos fails to hire, train, and retain qualified sales personnel, market our product successfully or on a cost effective basis or otherwise terminates our relationship, our ability to generate revenue will be limited and we will need to identify and retain an alternative organization, or develop our own sales and marketing capability.
Investor Relations | Agile Therapeutics
Client and Syneos Health shall establish appropriate limitations on the amount of available credit. In the event a Syneos Health Sales Representative is unable to establish credit worthiness, Client shall determine if it nevertheless desires to have a credit card issued to such Syneos Health Sales Representative.
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.